ScholarLens Back to search
2006•Zhongguo xiandai yixue/Zhongguo xiandai yixue zazhiRequires access

Clinical study of Moxifloxacin in the treatment of elderly patients with community acquired pneumonia

Yi Ren

Open publisher page 0 citations

Abstract

[Objective] To evaluate the clinical efficacy and safety of Moxifloxacin in the treatment of elderly patients with community acquired pneumonia (CAP). [Methods] Elderly patients with CAP were treated with moxifloxacin or cefuroxime in a randomized controlled study. [Results] A total of 119 patients were enrolled in this study, 60 patients in Moxifloxacin group, 59 patients in Cefuroxime group. The cure rates and the effective rates of Moxifloxacin group and cefuroxime group were 50%, 39% (P 0.05) and 90%, 69% (P 0.05), respectively. The bacterial eradication rates of the two groups were 84% and 53%, respectively. The rates of adverse reaction in the two groups were 8%, 5% (P 0.05.), respectively. [Conclusion] Moxifloxacin is effective and safe for the treatment of elderly patients with CAP, which has a high clinical value.

About this research paper

What this paper is about

[Objective] To evaluate the clinical efficacy and safety of Moxifloxacin in the treatment of elderly patients with community acquired pneumonia (CAP). [Methods] Elderly patients with CAP were treated with moxifloxacin or cefuroxime in a randomized controlled study. [Results] A total of 119 patients were enrolled in this study, 60 patients in Moxifloxacin group, 59 patients in Cefuroxime group. The cure rates and the effective rates of Moxifloxacin group and cefuroxime group were 50%, 39% (P 0.05) and 90%, 69% (P 0.05), respectively. The bacterial eradication rates of the two groups were 84% and 53%, respectively. The rates of adverse reaction in the two groups were 8%, 5% (P 0.05.), respectively. [Conclusion] Moxifloxacin is effective and safe for the treatment of elderly patients with CAP, which has a high clinical value.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

[Objective] To evaluate the clinical efficacy and safety of Moxifloxacin in the treatment of elderly patients with community acquired pneumonia (CAP). [Methods] Elderly patients with CAP were treated with moxifloxacin or cefuroxime in a randomized controlled study. [Results] A total of 119 patients were enrolled in this study, 60 patients in Moxifloxacin group, 59 patients in Cefuroxime group. The cure rates and the effective rates of Moxifloxacin group and cefuroxime group were 50%, 39% (P 0.05) and 90%, 69% (P 0.05), respectively. The bacterial eradication rates of the two groups were 84% and 53%, respectively. The rates of adverse reaction in the two groups were 8%, 5% (P 0.05.), respectively. [Conclusion] Moxifloxacin is effective and safe for the treatment of elderly patients with CAP, which has a high clinical value.

Key concepts: Moxifloxacin, Cefuroxime, Medicine, Community-acquired pneumonia, Pneumonia, Internal medicine, Adverse effect, Bacterial pneumonia

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical study of Moxifloxacin in the treatment of elderly patients with community acquired pneumonia — Research Paper | ScholarLens